How to tell if a hepatitis-C-virus-infected patient will respond to therapy

December 22, 2008

Hepatitis C virus (HCV) causes hepatitis and increased risk of developing liver cancer. Current treatments are expensive, have severe side effects, and fail in about half the patients treated. However, the Virahep-C Study Group, at Saint Louis University, has now developed an approach that predicted the outcome of therapy, raising the possibility of a test to predict treatment response and reduce treatment failures, something that could save a great deal of pain and expense for HCV-infected patients.

The research team, led by John Tavis and Rajeev Aurora, used a method known as covariation analysis to analyze variation in the genome-wide amino-acid sequence of viruses isolated from HCV-infected patients before they underwent treatment. Using this approach, networks of covariation were found to associate with specific responses of the patients to treatment. The authors suggest that the data has implications for the development of a test to predict how an individual infected with HCV will respond to treatment and might help identify targets for new antiviral drugs. In an accompanying commentary, Thomas Oh and Charles Rice, at Rockefeller University, New York, discuss further the therapeutic implications of these data.
-end-
TITLE: Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans

AUTHOR CONTACT:
Rajeev Aurora
Saint Louis University School of Medicine, St. Louis, Missouri, USA.
Phone: (314) 977-8891; Fax: (314) 977-8717; E-mail: aurorar@slu.edu.

John E. Tavis
Saint Louis University School of Medicine, St. Louis, Missouri, USA.
Phone: (314) 977-8893; Fax: (314) 977-8717; E-mail: tavisje@slu.edu

MEDIA CONTACT:
Nancy Solomon
Communications Director
Saint Louis University Medical Center, St. Louis, Missouri, USA.
Phone: (314) 977-8017 (office), (314) 662-6525 (cell); E-mail: solomonn@slu.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=37085

ACCOMPANYING COMMENTARY
TITLE: Predicting response to hepatitis C therapy

AUTHOR CONTACT:
Charles M. Rice
The Rockefeller University, New York, New York, USA.
Phone: (212) 327-7046; Fax: (212) 327-7048; E-mail: ricec@rockefeller.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=38069

JCI Journals

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.